ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
CEO: Barry Balfe. Company website
ICON Public Limited Company (ICLR) trades at $164.11, down 3.28% on the day, as of Sep 20, 2026 13:46 UTC.
ICON Public Limited Company has a market capitalisation of $12.57B, calculated from the live ICLR share price and shares outstanding.
ICLR trades at a trailing P/E of 38.52, from earnings per share of $4.26 over the last twelve months.
ICON Public Limited Company generated revenue of $8.25B over the trailing twelve months, which puts the stock at 1.52 times sales.
ICLR has traded between $66.58 and $203.91 over the past 52 weeks, and the last price is 19.5% below that high.
Yes. ICON Public Limited Company keeps 3.99% of revenue as net income over the trailing twelve months.
Wall Street analysts rate ICLR Buy, with an average price target of $170.64, 4.0% above the current price.
ICON Public Limited Company is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in IE.
Barry Balfe is the chief executive of ICON Public Limited Company, which employs 40,200 people.
QFI Terminal shows ICLR with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ICLR in Terminal See plans